Advaxis (NASDAQ:ADXS) Stock Rating Reaffirmed by HC Wainwright

Advaxis (NASDAQ:ADXS)‘s stock had its “neutral” rating restated by investment analysts at HC Wainwright in a research note issued on Wednesday, AnalystRatings.com reports.

The analysts wrote, “We maintain our Neutral rating of ADXS and our 12-month price target of $4.30 per share. We derive our price target based on the average of two valuation methods: (1) price-sales multiple (6x 2026 sales estimate at 20% discount); and (2) price-earnings multiple (19x 2026 earnings estimate at 20% discount).””

A number of other analysts also recently commented on the company. ValuEngine downgraded Advaxis from a “buy” rating to a “hold” rating in a research report on Monday, June 3rd. Zacks Investment Research upgraded Advaxis from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a research report on Wednesday, February 20th.

ADXS opened at $2.57 on Wednesday. The firm has a market cap of $14.15 million, a price-to-earnings ratio of -0.13 and a beta of 3.67. Advaxis has a one year low of $2.36 and a one year high of $28.35.

Advaxis (NASDAQ:ADXS) last posted its earnings results on Tuesday, March 12th. The biotechnology company reported $0.18 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.43. The company had revenue of $19.69 million for the quarter. Advaxis had a negative return on equity of 101.51% and a negative net margin of 140.12%.

A number of institutional investors and hedge funds have recently bought and sold shares of ADXS. Vanguard Group Inc boosted its position in shares of Advaxis by 48.3% in the third quarter. Vanguard Group Inc now owns 2,630,658 shares of the biotechnology company’s stock worth $2,473,000 after buying an additional 857,026 shares during the period. BlackRock Inc. boosted its position in shares of Advaxis by 3.1% in the fourth quarter. BlackRock Inc. now owns 1,446,288 shares of the biotechnology company’s stock worth $275,000 after buying an additional 43,368 shares during the period. Two Sigma Investments LP boosted its position in shares of Advaxis by 2,468.2% in the fourth quarter. Two Sigma Investments LP now owns 369,815 shares of the biotechnology company’s stock worth $70,000 after buying an additional 355,415 shares during the period. Finally, Deutsche Bank AG boosted its position in shares of Advaxis by 5,970.3% in the fourth quarter. Deutsche Bank AG now owns 562,294 shares of the biotechnology company’s stock worth $106,000 after buying an additional 553,031 shares during the period. Institutional investors own 24.40% of the company’s stock.

Advaxis Company Profile

Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.

Featured Article: Stock Symbols and CUSIP Explained

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.